View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsEmbecta 配当と自社株買い配当金 基準チェック /36Embectaは配当を支払う会社で、現在の利回りは2.88%ですが、利益によって十分にカバーされています。前回の支払いは 13th September, 2023で、権利落ち日は24th August, 2023 。主要情報2.9%配当利回り0.3%バイバック利回り総株主利回り3.2%将来の配当利回り2.5%配当成長n/a次回配当支払日13 Sep 23配当落ち日24 Aug 23一株当たり配当金n/a配当性向72%最近の配当と自社株買いの更新お知らせ • Feb 06Embecta Corp. Announces Quarterly Cash Dividend, Payable on March 17, 2026Embecta Corp. has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on March 17, 2026 to stockholders of record at the close of business on February 27, 2026.お知らせ • Aug 08Embecta Corp. Declares Quarterly Cash Dividend, Payable on September 15, 2025The Board of Directors of Embecta Corp. has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on September 15, 2025 to stockholders of record at the close of business on August 29, 2025.お知らせ • May 09+ 1 more updateEmbecta Corp. Announces Quarterly Cash Dividend, Payable on June 13, 2025The Board of Directors of Embecta Corp. has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on June 13, 2025 to stockholders of record at the close of business on May 28, 2025.お知らせ • Feb 15+ 1 more updateEmbecta Corp. Declares Quarterly Cash Dividend, Payable on March 13, 2023Embecta Corp. have declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on March 13, 2023 to stockholders of record at the close of business on February 27, 2023.すべての更新を表示Recent updatesお知らせ • Feb 06Embecta Corp. Announces Quarterly Cash Dividend, Payable on March 17, 2026Embecta Corp. has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on March 17, 2026 to stockholders of record at the close of business on February 27, 2026.お知らせ • Dec 19Embecta Corp., Annual General Meeting, Feb 11, 2026Embecta Corp., Annual General Meeting, Feb 11, 2026.お知らせ • Nov 25+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2026Embecta Corp. provided earnings guidance for the fiscal year 2026. For the year, the company expects reported revenues of $1,071 million to $1,093 million.お知らせ • Nov 18Embecta Corp. Announces Board ChangesEmbecta Corp. announced that on November 17, 2025, David A. Albritton, a member of the board of directors of the company, the Corporate Governance and Nominating Committee of the Board and the Technology, Quality and Regulatory Committee of the Board, notified the Company of his intention to resign due to personal reasons, effective immediately. Mr. Albritton has served as a director of the Company since April 2022. Mr. Albritton’s resignation was not the result of any disagreement with the Company or any matter relating to its operations, policies or practices. On November 17, 2025, LTG (Ret.) David F. Melcher, a member of the Board and the Non-Executive Chairman of the Board, notified the Company of his decision not to stand for re-election at the Company’s 2026 annual meeting of stockholders. LTG Melcher has served as a director of the Company since April 2022. LTG Melcher’s decision not to stand for reelection was not the result of any disagreement with the Company or any matter relating to its operations, policies or practices. In connection with the resignation of Mr. Albritton, the size of the Board was decreased from nine to eight members. The Company’s independent directors expect to appoint Devdatt (Dev) Kurdikar as the Chairman of the Board and Dr. Claire Pomeroy as the Board’s Lead Independent Director, each effective upon LTG Melcher’s departure from the Board at the Company’s 2026 annual meeting of stockholders. Dr. Pomeroy and Mr. Kurdikar have served on the Board since April 2022. Dr. Pomeroy currently serves as Chair of the Corporate Governance and Nominating Committee and as a member of the Technology, Quality and Regulatory Committee, and Mr. Kurdikar currently serves as the President and Chief Executive Officer of the Company.お知らせ • Nov 12Embecta Corp. to Report Q4, 2025 Results on Nov 25, 2025Embecta Corp. announced that they will report Q4, 2025 results on Nov 25, 2025お知らせ • Aug 08Embecta Corp. Declares Quarterly Cash Dividend, Payable on September 15, 2025The Board of Directors of Embecta Corp. has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on September 15, 2025 to stockholders of record at the close of business on August 29, 2025.お知らせ • May 22Embecta Corp. Re-Affirms Earnings Guidance for the Fiscal Year 2025Embecta Corp. re-affirmed earnings guidance for the fiscal year 2025. For the year, the company expected Reported Revenues of $1,073 million - $1,090 million.お知らせ • May 09+ 1 more updateEmbecta Corp. Announces Quarterly Cash Dividend, Payable on June 13, 2025The Board of Directors of Embecta Corp. has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on June 13, 2025 to stockholders of record at the close of business on May 28, 2025.お知らせ • Apr 22Embecta Corp. to Report Q2, 2025 Results on May 09, 2025Embecta Corp. announced that they will report Q2, 2025 results on May 09, 2025お知らせ • Feb 06+ 1 more updateEmbecta Corp. Revises Earnings Guidance for the Fiscal Year 2025Embecta Corp. revised earnings guidance for the Fiscal Year 2025 . For the year, company expected Reported Revenues to be in range of $1,075 million to $1,092 million compared to $1,093 million to $1,110 million.お知らせ • Jan 24Embecta Corp. to Report Q1, 2025 Results on Feb 06, 2025Embecta Corp. announced that they will report Q1, 2025 results on Feb 06, 2025お知らせ • Dec 20Embecta Corp., Annual General Meeting, Feb 12, 2025Embecta Corp., Annual General Meeting, Feb 12, 2025. Location: the hilton short hills, 41 john f. kennedy parkway, short hills, new jersey, United Statesお知らせ • Dec 03Embecta Corp. Announces Executive ChangesEmbecta Corp. appointed Anthony Roth as Chief Accounting Officer and Corporate Controller of the Company and principal accounting officer of the Company, effective as of December 2, 2024. Prior to joining the Company, Mr. Roth, 51, served as Senior Vice President, Chief Accounting Officer for Ascential plc’s Digital Commerce business during 2023 and as Chief Accounting Officer and Corporate Controller for Summit Health, from 2020 to 2023. Prior to his time with Summit Health, he served as Senior Vice President, Finance and Corporate Controller with Phibro Animal Health Corporation. Mr. Roth, a certified public accountant, has also held various accounting and financial reporting positions across several companies, including Squarespace Inc., ConvaTec Inc. and Travelport Limited. In connection with the appointment of Mr. Roth, Jake Elguicze stepped down as the Company’s principal accounting officer, effective December 2, 2024. Mr. Elguicze will continue to serve as the Company’s Chief Financial Officer and principal financial officer.お知らせ • Dec 01Embecta Corp. announced delayed annual 10-K filingOn 11/29/2024, Embecta Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 26+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2025Embecta Corp. provided earnings guidance for the Fiscal Year 2025 . For the year, company expected Reported Revenues to be in range of $1,093 million to $1,110 million.お知らせ • Nov 13Embecta Corp. to Report Q4, 2024 Results on Nov 26, 2024Embecta Corp. announced that they will report Q4, 2024 results on Nov 26, 2024お知らせ • Sep 03Embecta Corp. Receives 510(k) Clearance from the U.S. Food and Drug Administration for Disposable Insulin Delivery SystemEmbecta Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary disposable insulin delivery system. Indicated for adults who require insulin to manage diabetes, including both type 1 (T1D) and type 2 (T2D), the system includes a tubeless patch pump design with a 300-unit insulin reservoir that was informed by feedback from people with T2D and their healthcare providers. The system includes a wearable, fully disposable patch pump that provides adjustable basal and bolus insulin for up to three days, depending on the needs of the user. The patch pump features a 300-unit insulin reservoir that accommodates people who have higher daily insulin needs, which is typically true of people with T2D. For such people, the on-market patch pumps may not hold enough insulin to meet their needs for three days. For example, a recent embecta-sponsored study showed that a 300-unit insulin reservoir would meet the needs of 64% of adults with T2D for three-day wear, while a 200-unit reservoir would only meet the needs of 38% of that same population. In addition to the patch pump, the system comprises a locked-down controller featuring Bluetooth wireless technology with a color touchscreen designed to create a simplified interface and user experience. embecta’s patch pump development program also includes plans for a closed-loop version including an insulin-dosing algorithm in a future FDA submission.お知らせ • Aug 09+ 1 more updateEmbecta Corp. Revises Earnings Guidance for the Fiscal Year 2024Embecta Corp. revised earnings guidance for the fiscal year 2024. For the fiscal year, the Company now expects revenues of $1,111 million to $1,116 million same as previous guidance of $1,111 million to $1,116 million.お知らせ • Jul 19Embecta Corp. to Report Q3, 2024 Results on Aug 09, 2024Embecta Corp. announced that they will report Q3, 2024 results on Aug 09, 2024お知らせ • May 10+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2024Embecta Corp. provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be $1,111 million -$1,116 million against previous guidance of $1,094 million- $1,116 million.お知らせ • Apr 24Embecta Corp. to Report Q2, 2024 Results on May 09, 2024Embecta Corp. announced that they will report Q2, 2024 results on May 09, 2024お知らせ • Feb 09+ 1 more updateEmbecta Corp. Updates Earnings Guidance for the Fiscal Year 2024Embecta Corp. updated earnings guidance for the fiscal year 2024. For the year 2024, the company expected revenues to be $1,094 million to $1,116 million against $1,085 million to $1,105 million previous guidance.お知らせ • Jan 25Embecta Corp. to Report Q1, 2024 Results on Feb 09, 2024Embecta Corp. announced that they will report Q1, 2024 results on Feb 09, 2024お知らせ • Jan 09Embecta Corp. Announces Food and Drug Administration 510(K) Submission for Insulin Patch PumpEmbecta Corp. announced that it has submitted a 510(k) premarket filing to the U.S. Food and Drug Administration (FDA) for a proprietary disposable insulin delivery system. embecta continues to advance its patch pump development program, with plans for a closed-loop version including an insulin-dosing algorithm in a future FDA submission.お知らせ • Dec 20Embecta Corp., Annual General Meeting, Feb 07, 2024Embecta Corp., Annual General Meeting, Feb 07, 2024, at 08:00 US Eastern Standard Time. Location: Hilton Short Hills, 41 John F. Kennedy Parkway Short Hills New Jersey United States Agenda: To consider the election as directors of the three nominees named in the attached proxy statement for a two-year term; to consider the ratification of the selection of the independent registered public accounting firm; to consider an advisory vote to approve named executive officer compensation; and to discuss the approval of an amendment to the Embecta 2022 Employee and Director Equity-Based Compensation Plan.お知らせ • Nov 22+ 2 more updatesEmbecta Corp. to Report Q4, 2023 Results on Nov 21, 2023Embecta Corp. announced that they will report Q4, 2023 results on Nov 21, 2023お知らせ • Aug 09+ 1 more updateEmbecta Corp. Revises Earnings Guidance for the Fiscal Year 2023Embecta Corp. revised earnings guidance for the fiscal year 2023. For the year, company expects revenue $1,107 Million to $1,113 Million against previous guidance for revenue to be in range of $1,101 Million to $1,113 Million.お知らせ • Jul 06Embecta Corp. Announces Resignation of Ajay Kumar as Chief Human Resources Officer, Effective July 16, 2023On June 29, 2023, Ajay Kumar, the Chief Human Resources Officer (CHRO) of Embecta Corp. and the Company mutually agreed to Mr. Kumar’s resignation from his role as CHRO, effective July 16, 2023.Reported Earnings • May 17Second quarter 2023 earnings released: EPS: US$0.24 (vs US$1.38 in 2Q 2022)Second quarter 2023 results: EPS: US$0.24 (down from US$1.38 in 2Q 2022). Revenue: US$277.1m (flat on 2Q 2022). Net income: US$14.0m (down 82% from 2Q 2022). Profit margin: 5.1% (down from 29% in 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 9.1% growth forecast for the Global Medical Equipment industry.Board Change • May 17High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • May 13+ 1 more updateEmbecta Corp. Revises Revenue Guidance for the Fiscal Year 2023Embecta Corp. revises revenue guidance for the fiscal year 2023. The company now expects revenue of $1,101 million- $1,113 million against previous forecast of $1,084 million - $1,107 million.お知らせ • Feb 15+ 1 more updateEmbecta Corp. Declares Quarterly Cash Dividend, Payable on March 13, 2023Embecta Corp. have declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on March 13, 2023 to stockholders of record at the close of business on February 27, 2023.Reported Earnings • Feb 15First quarter 2023 earnings releasedFirst quarter 2023 results: EPS: US$0.62. Revenue: US$275.7m (down 4.7% from 1Q 2022). Net income: US$35.2m (down 64% from 1Q 2022). Profit margin: 13% (down from 34% in 1Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 8.7% growth forecast for the Global Medical Equipment industry.Board Change • Jan 30High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Jan 25Embecta Corp. to Report Q1, 2023 Results on Feb 14, 2023Embecta Corp. announced that they will report Q1, 2023 results on Feb 14, 2023Board Change • Jan 05High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Valuation Update With 7 Day Price Move • Dec 05Investor sentiment improved over the past weekAfter last week's 22% share price gain to Mex$666, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 25x in the Medical Equipment industry globally.Board Change • Nov 16High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Board Change • Oct 28High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Oct 01Embecta Corp., Annual General Meeting, Feb 09, 2023Embecta Corp., Annual General Meeting, Feb 09, 2023.Reported Earnings • Aug 16Third quarter 2022 earnings releasedThird quarter 2022 results: Net income: US$62.4m (up US$62.4m from 3Q 2021). Over the next year, revenue is expected to shrink by 2.5% compared to a 19% growth forecast for the Medical Equipment industry in Mexico.お知らせ • Jul 06Embecta Corp. to Report Q3, 2022 Results on Aug 15, 2022Embecta Corp. announced that they will report Q3, 2022 results Pre-Market on Aug 15, 2022お知らせ • May 14Embecta Corp. Provides Revenue Guidance for the Last Six Months of Fiscal Year 2022Embecta Corp. provided revenue guidance for the last six months of fiscal year 2022. For the period, the company expects total revenue of approximately $555 million, representing a decrease of approximately 7.0%, as compared to total revenue of $596 million for the last six months of fiscal year 2021.お知らせ • Apr 20Embecta Corp. to Report Q2, 2022 Results on May 13, 2022Embecta Corp. announced that they will report Q2, 2022 results Pre-Market on May 13, 2022決済の安定と成長配当データの取得安定した配当: EMBC *は配当の支払いを開始したばかりなので、配当金の支払いが安定しているかどうかを判断するのは時期尚早です。増加する配当: EMBC *は配当の支払いを開始したばかりなので、配当金が増加するかどうかを判断するのは時期尚早です。 配当利回り対市場Embecta 配当利回り対市場EMBC * 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (EMBC *)2.9%市場下位25% (MX)0%市場トップ25% (MX)0%業界平均 (Medical Equipment)0%アナリスト予想 (EMBC *) (最長3年)2.5%注目すべき配当: EMBC *の配当金 ( 2.88% ) はMX市場の配当金支払者の下位 25% ( 2.17% ) よりも高くなっています。高配当: EMBC *の配当金 ( 2.88% ) はMX市場の配当金支払者の上位 25% ( 5.65% ) と比較すると低いです。株主への利益配当収益カバレッジ: EMBC *の配当金は、合理的な 配当性向 ( 71.9% ) により、利益によって賄われています。株主配当金キャッシュフローカバレッジ: EMBC *の 現金配当性向 ( 49% ) は比較的低く、配当金の支払いはキャッシュフローによって十分にカバーされています。高配当企業の発掘7D1Y7D1Y7D1YMX 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/08/13 02:42終値2023/05/16 00:00収益2023/06/30年間収益2022/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Embecta Corp. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Travis SteedBofA Global ResearchTravis SteedBofA Global ResearchMichael GormanBTIG4 その他のアナリストを表示
お知らせ • Feb 06Embecta Corp. Announces Quarterly Cash Dividend, Payable on March 17, 2026Embecta Corp. has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on March 17, 2026 to stockholders of record at the close of business on February 27, 2026.
お知らせ • Aug 08Embecta Corp. Declares Quarterly Cash Dividend, Payable on September 15, 2025The Board of Directors of Embecta Corp. has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on September 15, 2025 to stockholders of record at the close of business on August 29, 2025.
お知らせ • May 09+ 1 more updateEmbecta Corp. Announces Quarterly Cash Dividend, Payable on June 13, 2025The Board of Directors of Embecta Corp. has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on June 13, 2025 to stockholders of record at the close of business on May 28, 2025.
お知らせ • Feb 15+ 1 more updateEmbecta Corp. Declares Quarterly Cash Dividend, Payable on March 13, 2023Embecta Corp. have declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on March 13, 2023 to stockholders of record at the close of business on February 27, 2023.
お知らせ • Feb 06Embecta Corp. Announces Quarterly Cash Dividend, Payable on March 17, 2026Embecta Corp. has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on March 17, 2026 to stockholders of record at the close of business on February 27, 2026.
お知らせ • Dec 19Embecta Corp., Annual General Meeting, Feb 11, 2026Embecta Corp., Annual General Meeting, Feb 11, 2026.
お知らせ • Nov 25+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2026Embecta Corp. provided earnings guidance for the fiscal year 2026. For the year, the company expects reported revenues of $1,071 million to $1,093 million.
お知らせ • Nov 18Embecta Corp. Announces Board ChangesEmbecta Corp. announced that on November 17, 2025, David A. Albritton, a member of the board of directors of the company, the Corporate Governance and Nominating Committee of the Board and the Technology, Quality and Regulatory Committee of the Board, notified the Company of his intention to resign due to personal reasons, effective immediately. Mr. Albritton has served as a director of the Company since April 2022. Mr. Albritton’s resignation was not the result of any disagreement with the Company or any matter relating to its operations, policies or practices. On November 17, 2025, LTG (Ret.) David F. Melcher, a member of the Board and the Non-Executive Chairman of the Board, notified the Company of his decision not to stand for re-election at the Company’s 2026 annual meeting of stockholders. LTG Melcher has served as a director of the Company since April 2022. LTG Melcher’s decision not to stand for reelection was not the result of any disagreement with the Company or any matter relating to its operations, policies or practices. In connection with the resignation of Mr. Albritton, the size of the Board was decreased from nine to eight members. The Company’s independent directors expect to appoint Devdatt (Dev) Kurdikar as the Chairman of the Board and Dr. Claire Pomeroy as the Board’s Lead Independent Director, each effective upon LTG Melcher’s departure from the Board at the Company’s 2026 annual meeting of stockholders. Dr. Pomeroy and Mr. Kurdikar have served on the Board since April 2022. Dr. Pomeroy currently serves as Chair of the Corporate Governance and Nominating Committee and as a member of the Technology, Quality and Regulatory Committee, and Mr. Kurdikar currently serves as the President and Chief Executive Officer of the Company.
お知らせ • Nov 12Embecta Corp. to Report Q4, 2025 Results on Nov 25, 2025Embecta Corp. announced that they will report Q4, 2025 results on Nov 25, 2025
お知らせ • Aug 08Embecta Corp. Declares Quarterly Cash Dividend, Payable on September 15, 2025The Board of Directors of Embecta Corp. has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on September 15, 2025 to stockholders of record at the close of business on August 29, 2025.
お知らせ • May 22Embecta Corp. Re-Affirms Earnings Guidance for the Fiscal Year 2025Embecta Corp. re-affirmed earnings guidance for the fiscal year 2025. For the year, the company expected Reported Revenues of $1,073 million - $1,090 million.
お知らせ • May 09+ 1 more updateEmbecta Corp. Announces Quarterly Cash Dividend, Payable on June 13, 2025The Board of Directors of Embecta Corp. has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on June 13, 2025 to stockholders of record at the close of business on May 28, 2025.
お知らせ • Apr 22Embecta Corp. to Report Q2, 2025 Results on May 09, 2025Embecta Corp. announced that they will report Q2, 2025 results on May 09, 2025
お知らせ • Feb 06+ 1 more updateEmbecta Corp. Revises Earnings Guidance for the Fiscal Year 2025Embecta Corp. revised earnings guidance for the Fiscal Year 2025 . For the year, company expected Reported Revenues to be in range of $1,075 million to $1,092 million compared to $1,093 million to $1,110 million.
お知らせ • Jan 24Embecta Corp. to Report Q1, 2025 Results on Feb 06, 2025Embecta Corp. announced that they will report Q1, 2025 results on Feb 06, 2025
お知らせ • Dec 20Embecta Corp., Annual General Meeting, Feb 12, 2025Embecta Corp., Annual General Meeting, Feb 12, 2025. Location: the hilton short hills, 41 john f. kennedy parkway, short hills, new jersey, United States
お知らせ • Dec 03Embecta Corp. Announces Executive ChangesEmbecta Corp. appointed Anthony Roth as Chief Accounting Officer and Corporate Controller of the Company and principal accounting officer of the Company, effective as of December 2, 2024. Prior to joining the Company, Mr. Roth, 51, served as Senior Vice President, Chief Accounting Officer for Ascential plc’s Digital Commerce business during 2023 and as Chief Accounting Officer and Corporate Controller for Summit Health, from 2020 to 2023. Prior to his time with Summit Health, he served as Senior Vice President, Finance and Corporate Controller with Phibro Animal Health Corporation. Mr. Roth, a certified public accountant, has also held various accounting and financial reporting positions across several companies, including Squarespace Inc., ConvaTec Inc. and Travelport Limited. In connection with the appointment of Mr. Roth, Jake Elguicze stepped down as the Company’s principal accounting officer, effective December 2, 2024. Mr. Elguicze will continue to serve as the Company’s Chief Financial Officer and principal financial officer.
お知らせ • Dec 01Embecta Corp. announced delayed annual 10-K filingOn 11/29/2024, Embecta Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 26+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2025Embecta Corp. provided earnings guidance for the Fiscal Year 2025 . For the year, company expected Reported Revenues to be in range of $1,093 million to $1,110 million.
お知らせ • Nov 13Embecta Corp. to Report Q4, 2024 Results on Nov 26, 2024Embecta Corp. announced that they will report Q4, 2024 results on Nov 26, 2024
お知らせ • Sep 03Embecta Corp. Receives 510(k) Clearance from the U.S. Food and Drug Administration for Disposable Insulin Delivery SystemEmbecta Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary disposable insulin delivery system. Indicated for adults who require insulin to manage diabetes, including both type 1 (T1D) and type 2 (T2D), the system includes a tubeless patch pump design with a 300-unit insulin reservoir that was informed by feedback from people with T2D and their healthcare providers. The system includes a wearable, fully disposable patch pump that provides adjustable basal and bolus insulin for up to three days, depending on the needs of the user. The patch pump features a 300-unit insulin reservoir that accommodates people who have higher daily insulin needs, which is typically true of people with T2D. For such people, the on-market patch pumps may not hold enough insulin to meet their needs for three days. For example, a recent embecta-sponsored study showed that a 300-unit insulin reservoir would meet the needs of 64% of adults with T2D for three-day wear, while a 200-unit reservoir would only meet the needs of 38% of that same population. In addition to the patch pump, the system comprises a locked-down controller featuring Bluetooth wireless technology with a color touchscreen designed to create a simplified interface and user experience. embecta’s patch pump development program also includes plans for a closed-loop version including an insulin-dosing algorithm in a future FDA submission.
お知らせ • Aug 09+ 1 more updateEmbecta Corp. Revises Earnings Guidance for the Fiscal Year 2024Embecta Corp. revised earnings guidance for the fiscal year 2024. For the fiscal year, the Company now expects revenues of $1,111 million to $1,116 million same as previous guidance of $1,111 million to $1,116 million.
お知らせ • Jul 19Embecta Corp. to Report Q3, 2024 Results on Aug 09, 2024Embecta Corp. announced that they will report Q3, 2024 results on Aug 09, 2024
お知らせ • May 10+ 1 more updateEmbecta Corp. Provides Earnings Guidance for the Fiscal Year 2024Embecta Corp. provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be $1,111 million -$1,116 million against previous guidance of $1,094 million- $1,116 million.
お知らせ • Apr 24Embecta Corp. to Report Q2, 2024 Results on May 09, 2024Embecta Corp. announced that they will report Q2, 2024 results on May 09, 2024
お知らせ • Feb 09+ 1 more updateEmbecta Corp. Updates Earnings Guidance for the Fiscal Year 2024Embecta Corp. updated earnings guidance for the fiscal year 2024. For the year 2024, the company expected revenues to be $1,094 million to $1,116 million against $1,085 million to $1,105 million previous guidance.
お知らせ • Jan 25Embecta Corp. to Report Q1, 2024 Results on Feb 09, 2024Embecta Corp. announced that they will report Q1, 2024 results on Feb 09, 2024
お知らせ • Jan 09Embecta Corp. Announces Food and Drug Administration 510(K) Submission for Insulin Patch PumpEmbecta Corp. announced that it has submitted a 510(k) premarket filing to the U.S. Food and Drug Administration (FDA) for a proprietary disposable insulin delivery system. embecta continues to advance its patch pump development program, with plans for a closed-loop version including an insulin-dosing algorithm in a future FDA submission.
お知らせ • Dec 20Embecta Corp., Annual General Meeting, Feb 07, 2024Embecta Corp., Annual General Meeting, Feb 07, 2024, at 08:00 US Eastern Standard Time. Location: Hilton Short Hills, 41 John F. Kennedy Parkway Short Hills New Jersey United States Agenda: To consider the election as directors of the three nominees named in the attached proxy statement for a two-year term; to consider the ratification of the selection of the independent registered public accounting firm; to consider an advisory vote to approve named executive officer compensation; and to discuss the approval of an amendment to the Embecta 2022 Employee and Director Equity-Based Compensation Plan.
お知らせ • Nov 22+ 2 more updatesEmbecta Corp. to Report Q4, 2023 Results on Nov 21, 2023Embecta Corp. announced that they will report Q4, 2023 results on Nov 21, 2023
お知らせ • Aug 09+ 1 more updateEmbecta Corp. Revises Earnings Guidance for the Fiscal Year 2023Embecta Corp. revised earnings guidance for the fiscal year 2023. For the year, company expects revenue $1,107 Million to $1,113 Million against previous guidance for revenue to be in range of $1,101 Million to $1,113 Million.
お知らせ • Jul 06Embecta Corp. Announces Resignation of Ajay Kumar as Chief Human Resources Officer, Effective July 16, 2023On June 29, 2023, Ajay Kumar, the Chief Human Resources Officer (CHRO) of Embecta Corp. and the Company mutually agreed to Mr. Kumar’s resignation from his role as CHRO, effective July 16, 2023.
Reported Earnings • May 17Second quarter 2023 earnings released: EPS: US$0.24 (vs US$1.38 in 2Q 2022)Second quarter 2023 results: EPS: US$0.24 (down from US$1.38 in 2Q 2022). Revenue: US$277.1m (flat on 2Q 2022). Net income: US$14.0m (down 82% from 2Q 2022). Profit margin: 5.1% (down from 29% in 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 9.1% growth forecast for the Global Medical Equipment industry.
Board Change • May 17High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • May 13+ 1 more updateEmbecta Corp. Revises Revenue Guidance for the Fiscal Year 2023Embecta Corp. revises revenue guidance for the fiscal year 2023. The company now expects revenue of $1,101 million- $1,113 million against previous forecast of $1,084 million - $1,107 million.
お知らせ • Feb 15+ 1 more updateEmbecta Corp. Declares Quarterly Cash Dividend, Payable on March 13, 2023Embecta Corp. have declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on March 13, 2023 to stockholders of record at the close of business on February 27, 2023.
Reported Earnings • Feb 15First quarter 2023 earnings releasedFirst quarter 2023 results: EPS: US$0.62. Revenue: US$275.7m (down 4.7% from 1Q 2022). Net income: US$35.2m (down 64% from 1Q 2022). Profit margin: 13% (down from 34% in 1Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 8.7% growth forecast for the Global Medical Equipment industry.
Board Change • Jan 30High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Jan 25Embecta Corp. to Report Q1, 2023 Results on Feb 14, 2023Embecta Corp. announced that they will report Q1, 2023 results on Feb 14, 2023
Board Change • Jan 05High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Valuation Update With 7 Day Price Move • Dec 05Investor sentiment improved over the past weekAfter last week's 22% share price gain to Mex$666, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 25x in the Medical Equipment industry globally.
Board Change • Nov 16High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Board Change • Oct 28High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Oct 01Embecta Corp., Annual General Meeting, Feb 09, 2023Embecta Corp., Annual General Meeting, Feb 09, 2023.
Reported Earnings • Aug 16Third quarter 2022 earnings releasedThird quarter 2022 results: Net income: US$62.4m (up US$62.4m from 3Q 2021). Over the next year, revenue is expected to shrink by 2.5% compared to a 19% growth forecast for the Medical Equipment industry in Mexico.
お知らせ • Jul 06Embecta Corp. to Report Q3, 2022 Results on Aug 15, 2022Embecta Corp. announced that they will report Q3, 2022 results Pre-Market on Aug 15, 2022
お知らせ • May 14Embecta Corp. Provides Revenue Guidance for the Last Six Months of Fiscal Year 2022Embecta Corp. provided revenue guidance for the last six months of fiscal year 2022. For the period, the company expects total revenue of approximately $555 million, representing a decrease of approximately 7.0%, as compared to total revenue of $596 million for the last six months of fiscal year 2021.
お知らせ • Apr 20Embecta Corp. to Report Q2, 2022 Results on May 13, 2022Embecta Corp. announced that they will report Q2, 2022 results Pre-Market on May 13, 2022